This study focuses on patients with non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body (metastatic), and specifically has a certain genetic change called KRAS p.G12C mutation. The study compares two treatments: sotorasib (also known as AMG 510), which is taken as tablets by mouth, and docetaxel, which is given through an infusion into a vein. Patients may also receive dexamethasone, a medication that helps manage side effects.
The main goal of this research is to determine if sotorasib works better than docetaxel in treating this specific type of lung cancer. The study will measure how long the cancer can be controlled before it starts growing again and how long patients live with either treatment. During the study, doctors will also track changes in cancer-related symptoms such as breathing problems, coughing, and chest pain.
Throughout the study, patients will have regular medical check-ups and imaging tests to monitor their cancer. The research team will evaluate how well each treatment works by looking at changes in tumor size and watching for signs that the cancer is growing or spreading. They will also assess how the treatments affect patients’ daily activities and overall well-being.
France 
Germany 
Greece 
Italy 
Poland 
Spain 
Sweden 
The Netherlands 
